Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD

Autophagy

Volumn 6, Issue 4, 2010, Pages 523-541

  Amarnath, Shoba ^a   Flomerfelt, Francis A ^a   Costanzo, Carliann M ^a   Foley, Jason E ^a   Mariotti, Jacopo ^a   Konecki, Daniel M ^a   Gangopadhyay, Anu ^a   Eckhaus, Michael ^b   Wong, Susan ^c   Levine, Bruce L ^d   June, Carl H ^d   Fowler, Daniel H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis resistance; Autophagy; Rapamycin; Th1 Tc1; Xenogeneic GVHD

Indexed keywords

ALPHA INTERFERON; BAG 1 PROTEIN; BECLIN 1; INTERLEUKIN 12; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAK; PROTEIN BAX; RAPAMYCIN; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT4 PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DIFFERENTIATION; ENGRAFTMENT; ENZYME ACTIVATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE; LIVER; LYMPHOCYTIC INFILTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN; T LYMPHOCYTE; TH1 CELL; XENOGRAFT;

MURINAE;

EID: 77953714876     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.6.4.11811     Document Type: Article

References (58)

1. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270:815-22.
2. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-47.
3. Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 2005; 175:5732-43. (Pubitemid 41508056)
4. Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, et al. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol Blood Marrow Transplant 2006; 12:905-18. (Pubitemid 44241766)
5. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162:2775-84.
6. Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, et al. Ex vivo rapamycin generates apoptosisresistant donor th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol 2008; 180:89-105.
7. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, et al. Sirolimus, tacrolimus and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102:1601-5. (Pubitemid 37022548)
8. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767-74.
9. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-87.
10. Rogge L, D'Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 1998; 161:6567-74. (Pubitemid 28562196)
11. Tyler DR, Persky ME, Matthews LA, Chan S, Farrar JD. Pre-assembly of STAT4 with the human IFNalpha/ beta receptor-2 subunit is mediated by the STAT4 N-domain. Mol Immunol 2007; 44:1864-72.
12. Ramos HJ, Davis AM, George TC, Farrar JD. IFNalpha is not sufficient to drive Th1 development due to lack of stable T-bet expression. J Immunol 2007; 179:3792-803.
13. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graftversus-host disease. J Exp Med 1992; 175:405-13.
14. + lymphoid engraftment. J Immunol 1994; 152:1004-13.
15. -/- double-mutant mice. Blood 2003; 102:2522-31.
16. Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, et al. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood 2005; 106:2433-5.
17. Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, et al. Factors affecting human T cell engraftment, trafficking and associated xenogeneic graft-vshost disease in NOD/SCID beta2mnull mice. Exp Hematol 2007; 35:1823-38.
18. + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. Journal of Immunology 1996; 157:4811-21.
19. Staruch MJ, Sigal NH, Dumont FJ. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. Int J Immunopharmacol 1991; 13:677-85.
20. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:1298-302. (Pubitemid 29535608)
21. L induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. J Biol Chem 2004; 279:910-9.
22. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17:1841-54.
23. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005; 201:259-66.
24. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nature Medicine 2002; 8:47-53.
25. +- selected hematopoietic cell transplantation. Blood 2003; 102:2004-13.
26. + T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12:1150-60.
27. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107:1325-31.
28. L. Immunity 1995; 3:87-98.
29. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96:785-93.
30. + T cells in the absence of exogenous feeder cells. J Immunol 1997; 159:5921-30.
31. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006; 57:225-44.
32. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008; 9:513-21. (Pubitemid 351560520)
33. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc and pim-1 genes in human T cells. Blood 1999; 93:1980-91. (Pubitemid 29128500)
34. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokinemediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358-63. (Pubitemid 47104613)
35. + regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 2003; 171:3435-41.
36. Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem 1995; 270:2320-6.
37. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-75. (Pubitemid 351317450)
38. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19:5720-8.
39. Toth B, Garabuczi E, Sarang Z, Vereb G, Vamosi G, Aeschlimann D, et al. Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol 2009; 182:2084-92.
40. Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA 1982; 79:1889-92.
41. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc 1993; 25:1216-7.
42. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
43. + T cells. Blood 2008; 111:453-62.
44. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009; 4:5994.
45. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versushost disease- and graft-versus-leukemia- causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol 1998; 160:5355-65. (Pubitemid 28267824)
46. Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S, et al. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an IL-4/STAT6 pathway. Blood 2008.
47. Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci USA 2004; 101:3011-6. (Pubitemid 38327726)
48. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105:4477-83.
49. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180:5794-8.
50. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an antiapoptotic effect. Eur J Cancer 2001; 37:2121-8. (Pubitemid 32938119)
51. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292:727-30. (Pubitemid 32385543)
52. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3:932-9. (Pubitemid 35154006)
53. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120:237-48. (Pubitemid 40174766)
54. + T cells and important for the growth factor-withdrawal cell death. J Immunol 2006; 177:5163-8.
55. Chen W, Frank ME, Jin W, Wahl SM. TGFbeta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14:715-25. (Pubitemid 32592419)
56. - T Cells. Retrovirology 2007; 4:57.
57. Hildeman DA, Mitchell T, Teague TK, Hanson P, Day BJ, Kappler J, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999; 10:735-44. (Pubitemid 29302926)
58. Hildeman DA. Regulation of T-cell apoptosis by reactive oxygen species. Free Radic Biol Med 2004; 36:1496-504.